Early response to new biologics for Crohn's disease pain
Treatments studied
Part of Digestive system clinical trials.
This study looks at how well new biologic medicines (vedolizumab or IL-23 blockers) work for people with Crohn's disease who are starting them for the first time. It tracks pain and other symptoms to see early responses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with Crohn's disease.
- Your doctor plans to start you on a new biologic medicine like vedolizumab or an IL-23 blocker (ustekinumab, risankizumab, guselkumab).
- You have pain from Crohn's that interferes with your daily activities (score at least 15 on a pain questionnaire).
- You have completed all standard tests for starting a biologic (like TB and infection checks).
- You have not had surgery for Crohn's disease planned during the study, and you have not already tried other advanced therapies (except some TNF blockers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining vedolizumab with adalimumab or ustekinumab helps people with moderate to severe Crohn's disease who haven't responded to other treatments. It aims to find better ways to manage symptoms and improve quality of life.
This study follows patients with moderate-to-severe Crohn's disease who are starting a newer type of biologic medication called IL-23 inhibitors (guselkumab or risankizumab). Researchers want to understand how well these drugs work in real-world clinical practice and compare their effectiveness to other treatments.
This study tests a new targeted therapy for adults with moderate to severe Crohn's disease who haven't responded well to other treatments. It aims to reduce inflammation and improve symptoms.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This Phase 3 study tests whether vedolizumab can better control moderate-to-severe Crohn’s disease in adults whose symptoms haven’t improved enough with other treatments. You’d need to meet specific symptom scores, recent colonoscopy findings, and safety checks (including infections and vaccination status).
This study tests two oral/ injectable medicines (upadacitinib and risankizumab) in adults with moderate-to-severe Crohn's who have already tried a TNF-blocker. It aims to see how well these treatments work in everyday practice.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.